Terrie Curran is CEO & President at Phathom Pharmaceuticals, Inc. (PHAT). They have made 15 open-market trades across 4 companies since 2017, most recently 2026-08-27.
CIK 0001690298
2 open-market purchases totalling $354K since 2022, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CELG | 37,181 | $4.0M |
| PHAT | 360,465 | $2.5M |
| ARQT | 23,526 | $679K |
| MYOV | 9,859 | $266K |
| Total | $7.5M |
Shares reported on the most recent Form 4, priced at the 2026-08-28 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARQT | SELL | 2026-08-27 | 2026-08-28 | $25.03 | $956K | -1.1% | +15.9% | — |
| ARQT | SELL | 2026-08-20 | 2026-08-24 | $26.04 | $28K | -5.4% | +5.4% | — |
| PHAT | SELL | 2025-01-21 | 2025-01-23 | $6.59 | $252K | -15.4% | -25.3% | -43.8% |
| ARQT | SELL | 2024-11-11 | 2024-11-13 | $10.85 | $189K | +3.5% | +21.9% | +9.5% |
| PHAT | SELL | 2024-07-15 | 2024-07-17 | $11.72 | $793K | -3.7% | +4.6% | +31.6% |
| PHAT | SELL | 2024-03-22 | 2024-03-26 | $9.11 | $307K | +7.6% | -11.9% | +4.8% |
| PHAT | BUY | 2023-04-06 | 2023-04-07 | $7.82 | $202K | +38.5% | +59.4% | +78.2% |
| PHAT | SELL · 10b5-1 | 2023-03-01 | 2023-03-03 | $8.54 | $12K | -21.3% | -16.5% | +30.8% |
| PHAT | SELL | 2023-01-20 | 2023-01-20 | $8.20 | $48K | +37.1% | +10.6% | +20.9% |
| PHAT | SELL | 2022-11-21 | 2022-11-23 | $9.60 | $15K | +12.4% | +15.9% | -2.9% |
| PHAT | BUY | 2022-05-13 | 2022-05-16 | $7.41 | $152K | -14.7% | -24.6% | +32.9% |
| MYOV | SELL | 2021-09-09 | 2021-09-13 | $25.58 | $248K | +2.4% | -5.5% | -36.0% |
| MYOV | SELL | 2021-09-01 | 2021-09-03 | $25.03 | $2.1M | -17.1% | -19.5% | -42.2% |
| PHAT | SELL | 2021-03-22 | 2021-03-23 | $43.32 | $998K | -16.0% | -10.8% | -17.4% |
| CELG | SELL | 2019-09-18 | 2019-09-19 | $98.28 | $1.8M | +0.6% | +4.8% | N/A |
| CELG | SELL | 2017-09-25 | 2017-09-26 | $143.89 | $497K | -3.4% | -30.6% | -25.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.